These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

287 related items for PubMed ID: 15824089

  • 1. Use of lopinavir/ritonavir in HIV-infected patients failing a first-line protease-inhibitor-containing HAART.
    Bongiovanni M, Chiesa E, Di Biagio A, Meraviglia P, Capetti A, Tordato F, Cicconi P, Biasi P, Bini T, d'Arminio Monforte A.
    J Antimicrob Chemother; 2005 Jun; 55(6):1003-7. PubMed ID: 15824089
    [Abstract] [Full Text] [Related]

  • 2. The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy.
    Staszewski S, Babacan E, Stephan C, Haberl A, Carlebach A, Gute P, Klauke S, Hermschulte Y, Stuermer M, Dauer B, Frankfurt HIV Cohort.
    J Antimicrob Chemother; 2006 Nov; 58(5):1024-30. PubMed ID: 16956902
    [Abstract] [Full Text] [Related]

  • 3. Antiretroviral treatment. HIV infection in adults: better-defined first-line treatment.
    Prescrire Int; 2004 Aug; 13(72):144-50. PubMed ID: 15532140
    [Abstract] [Full Text] [Related]

  • 4. Virological success of lopinavir/ritonavir salvage regimen is affected by an increasing number of lopinavir/ritonavir-related mutations.
    Bongiovanni M, Bini T, Adorni F, Meraviglia P, Capetti A, Tordato F, Cicconi P, Chiesa E, Cordier L, Cargnel A, Landonio S, Rusconi S, d'Arminio Monforte A.
    Antivir Ther; 2003 Jun; 8(3):209-14. PubMed ID: 12924537
    [Abstract] [Full Text] [Related]

  • 5. Positive virological outcome after lopinavir/ritonavir salvage therapy in protease inhibitor-experienced HIV-1-infected children: a prospective cohort study.
    Resino S, Bellón JM, Ramos JT, Gonzalez-Rivera M, de José MI, González MI, Gurbindo D, Mellado MJ, Cabrero E, Muñoz-Fernández MA.
    J Antimicrob Chemother; 2004 Nov; 54(5):921-31. PubMed ID: 15472006
    [Abstract] [Full Text] [Related]

  • 6. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S, Bernstein B, King M, Arribas J, Beall G, Ruane P, Johnson M, Johnson D, Lalonde R, Japour A, Brun S, Sun E, M98-863 Study Team.
    N Engl J Med; 2002 Jun 27; 346(26):2039-46. PubMed ID: 12087139
    [Abstract] [Full Text] [Related]

  • 7. Lopinavir/ritonavir monotherapy as a simplification strategy in routine clinical practice.
    Moltó J, Santos JR, Negredo E, Miranda C, Videla S, Clotet B.
    J Antimicrob Chemother; 2007 Aug 27; 60(2):436-9. PubMed ID: 17556354
    [Abstract] [Full Text] [Related]

  • 8. Long-term response to highly active antiretroviral therapy with lopinavir/ritonavir in pre-treated vertically HIV-infected children.
    Larrú B, Resino S, Bellón JM, de José MI, Fortuny C, Navarro ML, Gurbindo MD, Ramos JT, Soler Palacín P, Léon JA, Asensi M, Mellado MJ, Muñoz-Fernández MA.
    J Antimicrob Chemother; 2008 Jan 27; 61(1):183-90. PubMed ID: 18025025
    [Abstract] [Full Text] [Related]

  • 9. Salvage therapy with amprenavir, lopinavir and ritonavir 200 mg/d or 400 mg/d in HIV-infected patients in virological failure.
    Raguin G, Chêne G, Morand-Joubert L, Taburet AM, Droz C, Le Tiec C, Clavel F, Girard PM, Puzzle 1 Study Group.
    Antivir Ther; 2004 Aug 27; 9(4):615-25. PubMed ID: 15456093
    [Abstract] [Full Text] [Related]

  • 10. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J, Flandre P, Cohen-Codar I, Girard PM, Chaix ML, Raffi F, Dellamonica P, Ngovan P, Norton M, Delfraissy JF, MONARK Study Group.
    HIV Med; 2010 Feb 27; 11(2):137-42. PubMed ID: 19682100
    [Abstract] [Full Text] [Related]

  • 11. Predictive factors of lopinavir/ritonavir discontinuation for drug-related toxicity: results from a cohort of 416 multi-experienced HIV-infected individuals.
    Bongiovanni M, Cicconi P, Landonio S, Meraviglia P, Testa L, Di Biagio A, Chiesa E, Tordato F, Bini T, Monforte Ad.
    Int J Antimicrob Agents; 2005 Jul 27; 26(1):88-91. PubMed ID: 15878262
    [Abstract] [Full Text] [Related]

  • 12. Safety, efficacy and development of resistance under the new protease inhibitor lopinavir/ritonavir: 48-week results.
    Voigt E, Wasmuth JC, Vogel M, Mauss S, Schmutz G, Kaiser R, Rockstroh JK.
    Infection; 2004 Apr 27; 32(2):82-8. PubMed ID: 15057572
    [Abstract] [Full Text] [Related]

  • 13. Lopinavir/ritonavir monotherapy or plus zidovudine and lamivudine in antiretroviral-naive HIV-infected patients.
    Delfraissy JF, Flandre P, Delaugerre C, Ghosn J, Horban A, Girard PM, Norton M, Rouzioux C, Taburet AM, Cohen-Codar I, Van PN, Chauvin JP.
    AIDS; 2008 Jan 30; 22(3):385-93. PubMed ID: 18195565
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
    Landman R, Capitant C, Descamps D, Chazallon C, Peytavin G, Katlama C, Pialoux G, Bentata M, Brun-Vézinet F, Aboulker JP, Yéni P, ANRS 127 Study Group.
    J Antimicrob Chemother; 2009 Jul 30; 64(1):118-25. PubMed ID: 19420019
    [Abstract] [Full Text] [Related]

  • 15. Liver injury and changes in hepatitis C Virus (HCV) RNA load associated with protease inhibitor-based antiretroviral therapy for treatment-naive HCV-HIV-coinfected patients: lopinavir-ritonavir versus nelfinavir.
    Sherman KE, Shire NJ, Cernohous P, Rouster SD, Omachi JH, Brun S, Da Silva B.
    Clin Infect Dis; 2005 Oct 15; 41(8):1186-95. PubMed ID: 16163639
    [Abstract] [Full Text] [Related]

  • 16. [Lopinavir/ritonavir in HIV-infected patient with long-term virological failure: immunovirological response and tolerance in 121 patients of the ANRS CO8 Aproco-Copilote cohort].
    Brunet-François C, Taieb A, Masquelier B, Le Moing V, Lewden C, Dellamonica P, Cuzin L, Allavena C, Spire B, Chêne G, Raffi F, Groupe d'Etude Aproco-Copilote (ANRS C08).
    Med Mal Infect; 2007 Mar 15; 37(3):172-7. PubMed ID: 17239554
    [Abstract] [Full Text] [Related]

  • 17. Mutations at codons 54 and 82 of HIV protease predict virological response of HIV-infected children on salvage lopinavir/ritonavir therapy.
    Luis Jiménez J, Resino S, Martinez-Colom A, Bellón JM, Angeles Muñoz-Fernández M, Spanish Group of Paediatric HIV Infection.
    J Antimicrob Chemother; 2005 Dec 15; 56(6):1081-6. PubMed ID: 16195257
    [Abstract] [Full Text] [Related]

  • 18. Lopinavir-ritonavir monotherapy versus lopinavir-ritonavir and two nucleosides for maintenance therapy of HIV.
    Pulido F, Arribas JR, Delgado R, Cabrero E, González-García J, Pérez-Elias MJ, Arranz A, Portilla J, Pasquau J, Iribarren JA, Rubio R, Norton M, OK04 Study Group.
    AIDS; 2008 Jan 11; 22(2):F1-9. PubMed ID: 18097218
    [Abstract] [Full Text] [Related]

  • 19. Long-term follow-up of 414 HIV-infected Romanian children and adolescents receiving lopinavir/ritonavir-containing highly active antiretroviral therapy.
    Kline MW, Rugina S, Ilie M, Matusa RF, Schweitzer AM, Calles NR, Schwarzwald HL.
    Pediatrics; 2007 May 11; 119(5):e1116-20. PubMed ID: 17420261
    [Abstract] [Full Text] [Related]

  • 20. Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients.
    Bénard A, Damond F, Campa P, Peytavin G, Descamps D, Lascoux-Combes C, Taieb A, Simon F, Autran B, Brun-Vézinet F, Chêne G, Matheron S, ANRS CO5 HIV-2 Cohort Study Group.
    AIDS; 2009 Jun 01; 23(9):1171-3. PubMed ID: 19349850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.